752 related articles for article (PubMed ID: 28799305)
21. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy.
Bucci L; Palmieri GC
Curr Med Res Opin; 1993; 13(2):109-18. PubMed ID: 8325041
[TBL] [Abstract][Full Text] [Related]
22. Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy.
Kang SH; Lee YB; Lee JH; Nam JY; Chang Y; Cho H; Yoo JJ; Cho YY; Cho EJ; Yu SJ; Kim MY; Kim YJ; Baik SK; Yoon JH
Aliment Pharmacol Ther; 2017 Nov; 46(9):845-855. PubMed ID: 28836723
[TBL] [Abstract][Full Text] [Related]
23. Systematic Review and Meta-Analysis on the Effects of Lactulose and Rifaximin on Patient-Reported Outcomes in Hepatic Encephalopathy.
Moon AM; Kim HP; Jiang Y; Lupu G; Bissram JS; Barritt AS; Tapper EB
Am J Gastroenterol; 2023 Feb; 118(2):284-293. PubMed ID: 36730910
[TBL] [Abstract][Full Text] [Related]
24. Rifaximin treatment in hepatic encephalopathy.
Bass NM; Mullen KD; Sanyal A; Poordad F; Neff G; Leevy CB; Sigal S; Sheikh MY; Beavers K; Frederick T; Teperman L; Hillebrand D; Huang S; Merchant K; Shaw A; Bortey E; Forbes WP
N Engl J Med; 2010 Mar; 362(12):1071-81. PubMed ID: 20335583
[TBL] [Abstract][Full Text] [Related]
25. Long-Term Effect of Rifaximin with and without Lactulose on the Active Bacterial Assemblages in the Proximal Small Bowel and Faeces in Patients with Minimal Hepatic Encephalopathy.
Schulz C; Schütte K; Vilchez-Vargas R; Vasapolli R; Malfertheiner P
Dig Dis; 2019; 37(2):161-169. PubMed ID: 30428474
[TBL] [Abstract][Full Text] [Related]
26. Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi-centre cohort.
Bajaj JS; O'Leary JG; Tandon P; Wong F; Kamath PS; Biggins SW; Garcia-Tsao G; Lai J; Fallon MB; Thuluvath PJ; Vargas HE; Maliakkal B; Subramanian RM; Thacker LR; Reddy KR
Aliment Pharmacol Ther; 2019 Jun; 49(12):1518-1527. PubMed ID: 31032966
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study.
Williams R; James OF; Warnes TW; Morgan MY
Eur J Gastroenterol Hepatol; 2000 Feb; 12(2):203-8. PubMed ID: 10741936
[TBL] [Abstract][Full Text] [Related]
28. Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence?
Gluud LL; Dam G; Borre M; Les I; Cordoba J; Marchesini G; Aagaard NK; Vilstrup H
Metab Brain Dis; 2013 Jun; 28(2):221-5. PubMed ID: 23275147
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study.
Poo JL; Góngora J; Sánchez-Avila F; Aguilar-Castillo S; García-Ramos G; Fernández-Zertuche M; Rodríguez-Fragoso L; Uribe M
Ann Hepatol; 2006; 5(4):281-8. PubMed ID: 17151582
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms, diagnosis and management of hepatic encephalopathy.
Prakash R; Mullen KD
Nat Rev Gastroenterol Hepatol; 2010 Sep; 7(9):515-25. PubMed ID: 20703237
[TBL] [Abstract][Full Text] [Related]
31. Optimal treatment of hepatic encephalopathy.
Waghray A; Waghray N; Kanna S; Mullen K
Minerva Gastroenterol Dietol; 2014 Mar; 60(1):55-70. PubMed ID: 24632768
[TBL] [Abstract][Full Text] [Related]
32. Treatment of Acute Hepatic Encephalopathy: Comparing the Effects of Adding Rifaximin to Lactulose on Patient Outcomes.
Courson A; Jones GM; Twilla JD
J Pharm Pract; 2016 Jun; 29(3):212-7. PubMed ID: 25586470
[TBL] [Abstract][Full Text] [Related]
33. ACP Journal Club. Adding rifaximin to lactulose increased reversal and decreased mortality in hepatic encephalopathy.
Kowdley KV; Burman BE
Ann Intern Med; 2013 Oct; 159(8):JC8. PubMed ID: 24126669
[No Abstract] [Full Text] [Related]
34. Rifaximin vs. lactulose in treatment of minimal hepatic encephalopathy.
Sidhu SS; Goyal O; Parker RA; Kishore H; Sood A
Liver Int; 2016 Mar; 36(3):378-85. PubMed ID: 26201713
[TBL] [Abstract][Full Text] [Related]
35. Rifaximin in the treatment of chronic hepatic encephalopathy.
Puxeddu A; Quartini M; Massimetti A; Ferrieri A
Curr Med Res Opin; 1995; 13(5):274-81. PubMed ID: 7555036
[TBL] [Abstract][Full Text] [Related]
36. [Effects of lactulose treatment on the course of subclinical hepatic encephalopathy].
Zeng Z; Li YY
Zhonghua Yi Xue Za Zhi; 2003 Jul; 83(13):1126-9. PubMed ID: 12921628
[TBL] [Abstract][Full Text] [Related]
37. Real-World Experience of the One-Year Efficacy of Rifaximin Add-On to Lactulose Is Superior to Lactulose Alone in Patients with Cirrhosis Complicated with Recurrent Hepatic Encephalopathy in Taiwan.
Chang C; Huang CH; Tseng HJ; Yang FC; Chien RN
J Pers Med; 2021 May; 11(6):. PubMed ID: 34071787
[TBL] [Abstract][Full Text] [Related]
38. Rifaximin for the treatment of hepatic encephalopathy.
de Melo RT; Charneski L; Hilas O
Am J Health Syst Pharm; 2008 May; 65(9):818-22. PubMed ID: 18436728
[TBL] [Abstract][Full Text] [Related]
39. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy.
Agrawal A; Sharma BC; Sharma P; Sarin SK
Am J Gastroenterol; 2012 Jul; 107(7):1043-50. PubMed ID: 22710579
[TBL] [Abstract][Full Text] [Related]
40. Combination of rifaximin and lactulose improves clinical efficacy and mortality in patients with hepatic encephalopathy.
Wang Z; Chu P; Wang W
Drug Des Devel Ther; 2019; 13():1-11. PubMed ID: 30587923
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
